user
menu
letter
Sign InRegister
langEnglisharrow

CTLA-4

CTLA-4

CTLA-4 詳細

Molecule Name
Cytotoxic T-Lymphocyte-Associated Antigen 4
分子の別称
CTLA4,CD152
Drug Development Progress
治験薬の数64
市販薬剤の数5
研究＆開発段階Approved
ターゲットの別称
Celiac Disease 3，Ligand And Transmembrane Spliced Cytotoxic T Lymphocyte Associated Antigen 4，Cytotoxic T-Lymphocyte Protein 4，CD152，Cytotoxic T-lymphocyte-associated antigen 4，CTLA4，CTLA-4，Cytotoxic T-Lymphocyte Associated Protein 4，Insulin-Dependent Diabetes Mellitus 12，Cytotoxic T Lymphocyte Associated Antigen 4 Short Spliced Form，Cytotoxic T-Lymphocyte-Associated Serine Esterase-4，CD152 Isoform，CD152 Antigen，CELIAC3，IDDM12，ALPS5，GRD4，GSE，CD，CTLA-4 Antigen
バックグランド
CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is also known as CD152 (Cluster of differentiation 152), is a protein receptor that downregulates the immune system. CTLA4 is a member of the immunoglobulin superfamily, which is expressed on the surface of Helper T cells and transmits an inhibitory signal to T cells. The protein contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. Alternate splice variants, encoding different isoforms. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function. Fusion proteins of CTLA4 and antibodies (CTLA4-Ig) have been used in clinical trials for rheumatoid arthritis.

CTLA-4 製品リスト

Species
  • Human（9）
  • Cynomolgus / Rhesus macaque（4）
  • Mouse（4）
  • Rat（2）
Tag
  • His Tag（6）
  • Fc Tag（4）
  • His Tag & Avi Tag（4）
  • Fc Tag & Avi Tag（3）
  • Mouse IgG Fc Tag（1）
  • Strep Tag（1）
Host
  • HEK293（19）
Conjugate
  • Unconjugated（11）
  • Biotin-labeled（7）
  • PE Labeled（1）
Grade
  • RUO（19）
Low Endotoxin
  • Yes（5）
  • No（14）
MoleculeCat. No.Product Name種HostStructurePurityActivitySize&Price
CTLA-4
HOTAvitag
CT4-H82E1
Biotinylated Human CTLA-4 Protein, His,Avitag™
Human
HEK293
SDS-PAGE
ELISABLI

$360.00

25ug
CTLA-4
HOT
CT4-H5255
Human CTLA-4 / CD152 Protein, Fc Tag, low endotoxin (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISABLI

$200.00

200ug
CTLA-4
HOT
CT4-H52H9
Human CTLA-4 / CD152 Protein, His Tag, active dimer, low endotoxin (Mass Spec & MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISABLI

$310.00

100ug
CTLA-4
HOTAvitag
CT4-H82E3
Biotinylated Human CTLA-4 Protein, His,Avitag™ (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISASPR

$540.00

25ug
CTLA-4
CT4-C5227
Cynomolgus / Rhesus macaque CTLA-4 Protein, His Tag (MALS verified)
Cynomolgus / Rhesus macaque
HEK293
MALSSDS-PAGE
ELISA

$200.00

200ug
CTLA-4
CT4-C5256
Cynomolgus / Rhesus macaque CTLA-4 Protein, Fc Tag, low endotoxin (MALS verified)
Cynomolgus / Rhesus macaque
HEK293
MALSSDS-PAGE
ELISA

$200.00

200ug
CTLA-4
Avitag
CT4-C82E5
Biotinylated Cynomolgus / Rhesus macaque CTLA-4 Protein, Avitag™,His Tag
Cynomolgus / Rhesus macaque
HEK293
SDS-PAGE
ELISA

$360.00

25ug
CTLA-4
Avitag
CT4-C82F3
Biotinylated Cynomolgus / Rhesus macaque CTLA-4 Protein, Fc,Avitag™ (MALS verified)
Cynomolgus / Rhesus macaque
HEK293
MALSSDS-PAGE
ELISA

$360.00

25ug
CTLA-4
CT4-H5229
Human CTLA-4 / CD152 Protein, His Tag, low endotoxin (Mass Spec & HPLC verified)
Human
HEK293
HPLCSDS-PAGE
ELISASPR

$185.00

100ug
CTLA-4
CT4-H5284
Human CTLA-4 / CD152 Protein, Twin-Strep Tag
Human
HEK293
SDS-PAGE
ELISA

$270.00

25ug
You Have Viewed 1-10 Of 19 Results
  • 1
  • 2

Can’t find what you need?

Submit your requirements and our technical
team will help.

お問い合わせRequest Customization
FAQ

When is a CTLA-4 inhibitor screening kit useful compared with developing an assay using recombinant proteins?

Recombinant CTLA-4 and ligand proteins provide flexibility when researchers need to establish or optimize their own binding or blocking assay configuration. The ACROBiosystems B7-1 [Biotinylated]: CTLA-4 Inhibitor Screening ELISA Kit provides a predefined competition ELISA format for evaluating inhibition of the CTLA-4–B7-1 interaction. The kit can support a standardized screening workflow, while individual recombinant proteins are appropriate when assay components or conditions need to be customized.

How can recombinant CTLA-4 proteins support anti-CTLA-4 antibody screening and characterization?

Recombinant CTLA-4 proteins can be incorporated into direct antibody-binding assays or CTLA-4–B7 competition assays, depending on the study objective. Selected ACROBiosystems CTLA-4 products have been evaluated for binding to ipilimumab and for inhibition of CTLA-4 interactions with B7 ligands under defined assay conditions. These data are specific to the products and assay configurations tested and should not be generalized across the entire CTLA-4 portfolio.

Which CTLA-4 protein species are suitable for human and preclinical studies?

Species selection should match the therapeutic target and biological model being evaluated. ACROBiosystems provides recombinant CTLA-4 proteins from human, cynomolgus/rhesus macaque, mouse, and rat, supporting human-target studies and cross-species evaluation in relevant preclinical models. When comparing binding across species, comparable constructs and assay configurations can help reduce variability introduced by reagent format.

How do tag and labeling formats affect the selection of recombinant CTLA-4 proteins?

The protein format should be matched to the immobilization, capture, and detection strategy of the assay. ACROBiosystems offers CTLA-4 proteins with His, Fc, Strep, and Avi-tag configurations, including biotinylated and PE-labeled formats for compatible assay designs. Researchers should review the construct and product-specific validation data when selecting a format for binding, screening, or detection applications.

Should B7-1/CD80 or B7-2/CD86 be used for CTLA-4 binding and blocking assays?

Both B7-1/CD80 and B7-2/CD86 are physiological ligands of CTLA-4, so ligand selection should reflect the interaction and assay model being studied. Selected ACROBiosystems CTLA-4 proteins include product-specific binding data against B7-1 and/or B7-2 that can help assess suitability for a planned assay. For blocking studies, maintaining a consistent CTLA-4–B7 pair is important when comparing antibody or inhibitor activity.

What types of assays can recombinant CTLA-4 proteins support?

Recombinant CTLA-4 proteins can support receptor–ligand binding studies, antibody-binding assays, and blocking or inhibitor screening assays involving the CTLA-4 pathway. ACROBiosystems provides CTLA-4 proteins in multiple species, tag, and labeling formats, together with complementary inhibitor screening reagents. The appropriate protein format should be selected according to the interaction being measured and the planned assay configuration.
Asset Licensing Opportunity
Resources

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
CS-1002CS-1002; SHR-8068Phase 3 ClinicalCstone Pharmaceuticals
Adenocarcinoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Neoplasms; Rectal Neoplasms; Solid tumours; Stomach Neoplasms; Uterine Cervical Neoplasms
詳細
BotensilimabAGEN-1181Phase 3 ClinicalAgenus Inc
Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Fibrolamellar hepatocellular carcinoma; Glioblastoma; Gliosarcoma; Hemangiosarcoma; Liver Neoplasms; Melanoma; Microsatellite Instability; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Solid tumours; Stomach Neoplasms; Uterine Cervical Neoplasms
詳細
Sturlimogene ErparepvecRP-2Phase 3 ClinicalReplimune Group Inc
Colorectal Neoplasms; Esophageal adenocarcinoma; Gastroesophageal Junction Neoplasms; Neoplasms; Precancerous Conditions; Stomach Neoplasms; Uveal melanoma
詳細
GotistobartONC-392; BNT316; BNT-316Phase 3 ClinicalOncoimmune Inc
Anorectal disorders; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Cystadenocarcinoma, Serous; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Melanoma; Metastatic breast cancer; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Salivary Gland Neoplasms; Sarcoma; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Uterine Cervical Neoplasms
詳細
ErfonrilimabKN-046Phase 3 ClinicalJiangsu Alphamab Biopharmaceuticals Co Ltd
Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastrointestinal Neoplasms; Lymphoma; Neuroendocrine Tumors; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Thymoma; Thymus Neoplasms; Triple Negative Breast Neoplasms
詳細
VolrustomigMEDI5752; MEDI-5752Phase 3 ClinicalMedimmune Llc
Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Mesothelioma; Papillomavirus Infections; Sarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uterine Cervical Neoplasms
詳細
Ipilimumab biosimilar (Henlius)HLX13Phase 3 Clinical
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Liver Neoplasms; Melanoma; Mesothelioma; Solid tumours
詳細
Nurulimab/ProlgolimabBCD-217; BCD-145/BCD-100Phase 3 ClinicalBIOCAD JSC
Melanoma; Skin Melanoma
詳細
Pembrolizumab/QuavonlimabMK-1308APhase 3 ClinicalMerck Sharp & Dohme Corp, Msd Ireland (Carlow), MSD R&D（China）Co Ltd
Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Melanoma; Small Cell Lung Carcinoma; Solid tumours
詳細
FutermestotugYH-001Phase 2 Clinical
Alopecia Areata; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Sarcoma; Solid tumours
詳細
DanvilostomigSI-B003Phase 2 ClinicalSichuan Baili Pharmaceutical Co Ltd
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Metastatic breast cancer; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms
詳細
BMS-986288BMS-986288Phase 2 ClinicalCytomx Therapeutics Inc
Neoplasms
詳細
EvalstotugCAB-CTLA-4; BA-3071Phase 2 ClinicalBeOne Medicines Ltd, Bioatla
Carcinoma, Non-Small-Cell Lung; Melanoma
詳細
VudalimabXmAb-717; XmAb-20717; XmAb 717Phase 2 ClinicalXencor Inc
Adenocarcinoma, Clear Cell; Adenoma, Acidophil; Adnexal Diseases; Astrocytoma; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Castration-Sensitive Prostate Neoplasms; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Melanoma; Mesothelioma; Nasopharyngeal Carcinoma; Ovarian Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thymoma; Thyroid Neoplasms; Uterine Cervical Neoplasms; Vulvar Neoplasms
詳細
Recombinant anti-CTLA-4 human monoclonal antibody (Hualan Biological Engineering)Phase 2 ClinicalHualan Ankang Biotechnology Co Ltd
Melanoma
詳細
LorigerlimabMGD-019; AEX1344Phase 2 ClinicalMacrogenics Inc
Adenocarcinoma, Clear Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Hormone-Resistant Prostate Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Ovarian Clear Cell Carcinoma; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Skin Melanoma; Solid tumours; Uterine Cervical Neoplasms
詳細
Belatacept biosimilar (Alphamab)KN-019Phase 2 ClinicalSuzhou Alphamab Co Ltd
Arthritis, Rheumatoid; Rejection of renal transplantation
詳細
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital)Phase 2 ClinicalChanghai Hospital of Navy Medical University
Pancreatic Neoplasms
詳細
Abatacept (Orban Biotech)Phase 2 ClinicalOrban Biotech, The National Institute Of Diabetes And Digestive And Kidney Diseases
Diabetes Mellitus, Type 1
詳細
QuavonlimabAK-107; MK-1308Phase 2 Clinical
Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Melanoma; Neoplasms; Small Cell Lung Carcinoma; Solid tumours
詳細
ZalifrelimabAGEN-1884; RebmAb-600; UGN-301Phase 2 Clinical4-Antibody AG, Ludwig Institute For Cancer Research
Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Hemangiosarcoma; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms
詳細
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute)Phase 2 ClinicalShanghai Cell Therapy Research Institute
Neoplasms
詳細
KD-6001KD-6001Phase 2 ClinicalShanghai Celgen Bio-Pharmaceutical Co Ltd, Shanghai Kanda Bio-Technology Co Ltd
Carcinoma, Hepatocellular; Liver Neoplasms; Melanoma; Neoplasms; Solid tumours
詳細
PorustobartHBM-4003; HCAb 4003-2Phase 2 ClinicalHarbour Biomed
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Melanoma; Neoplasms; Neuroendocrine Tumors; Solid tumours
詳細
JK-08JK-08Phase 2 ClinicalXinlitai (Chengdu) Biological Technology Co Ltd
Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Triple Negative Breast Neoplasms
詳細
SovipostobartBMS-986249Phase 2 ClinicalCytomx Therapeutics Inc
Neoplasms
詳細
GI-101SIM-323; SIM323; SIM0323; GI-101Phase 2 ClinicalGI Innovation Inc
Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Solid tumours; Uterine Cervical Neoplasms
詳細
ApalulizumabPhase 2 ClinicalShanghai Rui Jin Hospital
Pancreatic Neoplasms
詳細
FirastotugADG-116Phase 2 ClinicalAdagene (Suzhou) Ltd
Solid tumours
詳細
LM-168LM-168Phase 2 ClinicalLaNova Medicines Ltd
Solid tumours
詳細
HX-044HX044; HX-044Phase 2 ClinicalHanx Biopharmaceuticals Pty Ltd
Lymphoma; Solid tumours
詳細
EGL-001EGL-001Phase 2 ClinicalEgle Therapeutics
Neoplasms; Solid tumours
詳細
CS-2009CS-2009Phase 2 ClinicalCstone Pharmaceuticals
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Triple Negative Breast Neoplasms
詳細
COYA-302COYA 302; COYA-302; COYA302Phase 2 ClinicalCoya Therapeutics Inc
Amyotrophic Lateral Sclerosis; Frontotemporal Dementia; Parkinson Disease
詳細
HC-010(Shanghai Hongcheng)HC-010; HC010Phase 2 ClinicalShanghai Hongcheng Pharmaceutical Co Ltd
Carcinoma, Non-Small-Cell Lung; Solid tumours
詳細
Efzilonkofusp alfaGI-102Phase 2 ClinicalGI Innovation Inc
Astrocytoma; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Glioblastoma; Gliosarcoma; Liver Neoplasms; Melanoma; Ovarian Neoplasms; Skin Melanoma; Soft Tissue Neoplasms; Solid tumours
詳細
SV-102SV-102; SV102; SYNC-T SV-102Phase 2 ClinicalSyncromune Inc
Prostatic Neoplasms, Castration-Resistant
詳細
Anti-CTLA-4/PD-1 expressing EGFR-CAR-TPhase 2 ClinicalShanghai Cell Therapy Research Institute
Solid tumours
詳細
IMM-27MIMM-27M; IMM27M; SYN27M; SYN-27MPhase 2 Clinical
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasms; Pathologic Processes; Solid tumours
詳細
VilastobartXTX-101; XTX101Phase 2 ClinicalXilio Development Inc
Colorectal Neoplasms
詳細
RP-3RP-3Phase 2 ClinicalReplimune Inc
Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck
詳細
MuzastotugADG-126Phase 2 ClinicalAdagene Inc
Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liver Neoplasms; Solid tumours
詳細
PD-L1 antibody combined with CTLA-4 antibody (Shanghai Zhongshan Hospital)Phase 2 ClinicalShanghai Zhongshan Hospital
Cholangiocarcinoma
詳細
JS-007JS007; JS-007Phase 2 ClinicalShanghai Junshi Biosciences Co Ltd
Carcinoma, Hepatocellular; Lung Neoplasms; Melanoma; Neoplasms; Pancreatic Neoplasms; Solid tumours
詳細
KN-044KN-044Phase 1 ClinicalSuzhou Alphamab Co Ltd
Small Cell Lung Carcinoma; Solid tumours
詳細
BavunalimabXmAb-22841; XmAb-841Phase 1 ClinicalXencor Inc
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Nasopharyngeal Carcinoma; Pancreatic Neoplasms; Penile Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms
詳細
Anti-CTLA-4 monoclonal antibody (Regeneron)REGN-4659Phase 1 ClinicalRegeneron Pharmaceuticals Inc
Carcinoma, Non-Small-Cell Lung
詳細
BMS-986218 (Bristol-Myers Squibb)BMS-986218Phase 1 ClinicalBristol-Myers Squibb Company
Adrenal Gland Neoplasms; Liver Neoplasms; Lung Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours
詳細
Ipilimumab biosimilar (Mab-Venture/ShuangLu Pharmaceutical)MV-049Phase 1 ClinicalBeijing Sl Pharmaceutical Co Ltd, Mab-Venture Biopharm Co Ltd
Solid tumours
詳細
SAL-008SAL-008Phase 1 ClinicalXinlitai (Chengdu) Biological Technology Co Ltd
Neoplasms
詳細
GIGA-564GIGA-564Phase 1 ClinicalGigaGen Inc
Solid tumours
詳細
CTLA-4 Mab (Beijng Immunoah Pharma Tech)5E3 (Beijng Immunoah Pharma Tech); CTLA-4 Mab (Beijng Immunoah Pharma Tech)Phase 1 ClinicalBeijng Immunoah Pharma Tech Co Ltd
Solid tumours
詳細
GB-268GB268Phase 1 ClinicalGenor Biopharma Co Ltd
Neoplasms; Solid tumours
詳細
A-337 (Klus Pharma)A337 (Klus Pharma); A-337 (Klus Pharma)Phase 1 ClinicalKlus Pharma Inc
Neoplasms
詳細
BZE-2209BZE-2209; BZE2209; αPD1/CTLA4-MSLN-CAR T CellsPhase 1 ClinicalShanghai Cell Therapy Group Co Ltd
Solid tumours
詳細
GK-201GK201; GK-201Phase 1 ClinicalSuzhou Guokuang Pharmaceutical Tech Co Ltd
Solid tumours
詳細
STW204/GotistobartAI-061Phase 1 ClinicalOncoc4 Inc
Anus Neoplasms; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Ovarian Neoplasms; Peritoneal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms
詳細
KM602KM602; KM-602; XZP-KM602Phase 1 ClinicalXuanzhu (Shijiazhuang) Biotechnology Co Ltd
Solid tumours
詳細
IMD-303IMD-303; IMD303Phase 1 ClinicalShanghai Affinity Biopharmaceutical Co Ltd
Solid tumours
詳細
Imiquimod/ZalifrelimabUGN-302; UGN-201+UGN-301Phase 1 ClinicalUrogen Pharma
Urinary Bladder Neoplasms
詳細
TWP-102TWP-102Phase 1 ClinicalTherawisdom Biopharma Co Ltd
Neoplasms
詳細
SKB-337SKB337; A-337; SKB-337Phase 1 ClinicalSichuan Kelun-Biotech Biopharmaceutical Co Ltd
Solid tumours
詳細
BAT-4706BAT-4706Phase 1 ClinicalBio-Thera Solutions Ltd
Melanoma; Solid tumours
詳細
B7-2/GM-CSF cancer gene therapyCITPhase 1 ClinicalRadient
Neoplasms
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
CadonilimabAK-104; AK104Approved开坦尼Mainland ChinaUterine Cervical NeoplasmsKangfang Pharmaceutical Co Ltd2022-06-29
Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Lung Neoplasms; Lymphoma, T-Cell, Peripheral; Melanoma; Mesothelioma; Microsatellite Instability; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Nasopharyngeal Carcinoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Diseases; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms; Vaginal Neoplasms; Vulvar Neoplasms
詳細
Ipilimumab10D1; MDX-CTLA-4; Anti-CTLA-4 Mab; BMS-734016; Mab-10D14; MDX-101; MDX-010ApprovedBristol-Myers Squibb CompanyYervoy, 逸沃United StatesMelanomaBristol-Myers Squibb Company2011-03-25
Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Mucinous; Adrenocortical Carcinoma; Angioimmunoblastic T-cell Lymphoma; Anus Neoplasms; Brain metastases; Breast Neoplasms; Burkitt Lymphoma; Carcinoma, Acinar Cell; Carcinoma, Adenoid Cystic; Carcinoma, Basal Cell; Carcinoma, Embryonal; Carcinoma, Endometrioid; Carcinoma, Giant Cell; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Carcinoma, Verrucous; Cholangiocarcinoma; Chordoma; Choriocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Cystadenocarcinoma; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Endodermal Sinus Tumor; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Neoplasms; Fibromatosis, Aggressive; Gallbladder Neoplasms; Gastrointestinal Stromal Tumors; Gestational Trophoblastic Disease; Glioblastoma; Gliosarcoma; Hemangiosarcoma; HIV I
詳細
IpilimumabN01 (Innovent Biologics)IBI-310ApprovedInnovent Biologics(Suzhou) Co Ltd达伯欣Mainland ChinaColonic NeoplasmsInnovent Biologics Inc2025-12-22
Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Liver Neoplasms; Melanoma; Microsatellite Instability; Mismatch Repair Deficient Cancer; Nasopharyngeal Carcinoma; Solid tumours; Stomach Neoplasms; Uterine Cervical Neoplasms
詳細
TremelimumabCP-675206; CP-675ApprovedPfizer IncIMJUDOUnited StatesCarcinoma, HepatocellularAstrazeneca Ab2022-10-21
Adenocarcinoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Bone metastases; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Cystadenoma, Serous; Digestive System Diseases; Dysgerminoma; Endometrial Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Gastroesophageal Junction Neoplasms; Genital Neoplasms, Female; Glioblastoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Hepatitis C, Chronic; HIV Infections; Hydronephrosis; Kidney Neoplasms; Klatskin Tumor; Laryngeal Diseases; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Cutaneous; Melanoma; Mesothelioma; Metastatic breast cancer; Microsatel
詳細
Iparomlimab/TuvonralimabPBS-103/PBS-105; QL-1706; PSB-205ApprovedQilu Pharmaceutical Co Ltd齐倍安Mainland ChinaUterine Cervical NeoplasmsQilu Pharmaceutical Co Ltd2024-09-26
Adenocarcinoma of Lung; Biliary Tract Neoplasms; Bone Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Diseases; Head and Neck Neoplasms; Liver Neoplasms; Lung Neoplasms; Melanoma; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Nasopharyngeal Carcinoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Rectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Intraepithelial Lesions of the Cervix; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms
詳細
Customer Reviews
  • J***o2023-02-03
    Human CTLA-4 / CD152 Protein, His Tag, low endotoxin (Mass Spec & HPLC verified)
    Bought as potential coating protein to be used in ELISA to detected expressed Anti-CTLA-4. Vials arrived promptly and very well packaged. The website is informative and very intuitive to navigate to be able to find the product best suited for your needs. MSDS, CofA and Dataheets are readily available and contain accurate and comprehensive information e.g. storage temperatures, glycosylation information and purity- the guidance for usage of the protein was especially useful to serve as a jumping off point for coating concentrations. Results so far have been very promising which is what I have come to expect from ACROBiosystems- great work!
  • J***r2022-01-11
    Human CTLA-4 / CD152 Protein, His Tag, low endotoxin (Mass Spec & HPLC verified)
    The product came in packaged properly and with proper documentation. CoAs were clear as to when the product would expire, both in the lyophilized state and reconstituted. Instructions for reconstitution were also clear. The packaging made it easy to quickly transfer the product to the appropriate storage. Package was shipped in a reasonable timeline. Details for the product were easy to find, which was extremely helpful for entering into our system.